Elan drops higher-dose trials of drug

Irish-based drug company Elan, as well as Transition Therapeutics, have dropped the two highest doses of their experimental Alzheimers drug from a clinical trial following nine deaths.

It raises doubts over whether or not the drug will now get to market.

The impact on Elan has been limited though as little value has so far been attributed to the product.

Patients will be withdrawn immediately from the higher dose study, whilst others on lower doses will continue.